IKNA · Ikena Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $800.0K | - | $3.50M | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.96M | - | $15.56M | $4.03M | $3.71M | - | $6.82M | $9.83M | $9.64M | - |
| SG&A | $6.12M | - | $11.04M | $4.42M | $5.64M | - | $4.78M | $5.31M | $6.00M | - |
| Total Operating Expenses | $12.08M | - | $26.59M | $8.75M | $10.79M | - | $12.41M | $15.82M | $18.23M | - |
| D&A | $2.0K | - | - | - | $87.0K | - | - | - | $219.0K | - |
| Operating Income | ($12.08M) | - | ($26.59M) | ($8.75M) | ($10.79M) | - | ($12.41M) | ($15.82M) | ($18.23M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $10.0K | - | ($74.0K) | $15.0K | $28.0K | - | $10.0K | $62.0K | $27.0K | - |
| Net Income | ($10.62M) | - | ($24.78M) | ($2.77M) | ($8.62M) | - | ($10.23M) | ($13.73M) | ($16.15M) | - |
| EPS - Basic | ($0.95) | - | ($2.91) | ($0.06) | ($0.18) | - | ($0.21) | ($0.28) | ($0.33) | - |
| EPS - Diluted | ($0.95) | - | ($2.91) | ($0.06) | ($0.18) | - | ($0.21) | ($0.28) | ($0.33) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $76.05M | $94.53M | $103.16M | $58.29M | $36.76M | $39.39M | $45.19M | $44.27M | $52.85M | $119.89M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $568.0K | $1.44M | $2.08M | $512.0K | $805.0K | $897.0K | $1.54M | $1.41M | $1.91M | $2.07M |
| Current Assets | $122.01M | $140.29M | $147.53M | $99.01M | $117.00M | $127.17M | $141.53M | $149.32M | $161.17M | $178.66M |
| Total Assets | $136.68M | $152.98M | $160.88M | $126.17M | $130.84M | $141.51M | $148.99M | $157.49M | $172.78M | $192.09M |
| Current Liabilities | $6.63M | $11.23M | $11.14M | $7.32M | $8.79M | $10.78M | $9.24M | $8.20M | $10.17M | $14.21M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $13.36M | $19.84M | $21.05M | $10.26M | $12.59M | $15.58M | $14.76M | $14.63M | $17.43M | $22.34M |
| Stockholders' Equity | $123.33M | $133.14M | $139.83M | $115.91M | $118.25M | $125.93M | $134.23M | $142.86M | $155.35M | $169.76M |
| Retained Earnings | ($240.67M) | ($230.05M) | ($223.14M) | ($343.00M) | ($340.24M) | ($331.62M) | ($322.50M) | ($312.26M) | ($298.53M) | ($282.38M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($14.80M) | - | - | - | ($10.56M) | - | - | - | ($18.30M) | - |
| Investing Cash Flow | ($440.0K) | - | - | - | $7.93M | - | - | - | ($48.74M) | - |
| Financing Cash Flow | $27.0K | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1509.9% | - | -759.8% | - | - | - | - | - | - | - |
| EBITDA margin | -1509.6% | - | - | - | - | - | - | - | - | - |
| Net margin | -1327.4% | - | -708.0% | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 745.1% | - | 444.5% | - | - | - | - | - | - | - |
| SG&A / Revenue | 764.8% | - | 315.3% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.8% | - | -15.4% | -2.2% | -6.6% | - | -6.9% | -8.7% | -9.3% | - |
| Return on equity | -8.6% | - | -17.7% | -2.4% | -7.3% | - | -7.6% | -9.6% | -10.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 18.39 | 12.49 | 13.24 | 13.52 | 13.31 | 11.80 | 15.32 | 18.22 | 15.85 | 12.58 |
| Quick ratio | 18.39 | 12.49 | 13.24 | 13.52 | 13.31 | 11.80 | 15.32 | 18.22 | 15.85 | 12.58 |
| Cash ratio | 11.46 | 8.41 | 9.26 | 7.96 | 4.18 | 3.65 | 4.89 | 5.40 | 5.20 | 8.44 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.11 | 1.15 | 1.15 | 1.09 | 1.11 | 1.12 | 1.11 | 1.10 | 1.11 | 1.13 |
| Liabilities / Assets | 0.10 | 0.13 | 0.13 | 0.08 | 0.10 | 0.11 | 0.10 | 0.09 | 0.10 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | - | 0.02 | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | -46.8% | - | -18.2% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | -24.3% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -11.9% | - | -114.3% | 44.7% | 40.8% | - | 36.4% | 14.4% | -17.5% | - |
| Net income growth (YoY) | -23.2% | - | -142.1% | 79.8% | 46.6% | - | 41.0% | 19.8% | -13.6% | - |
| EPS growth (YoY) | -427.8% | - | -1285.7% | 78.6% | 45.5% | - | 47.5% | 36.4% | 15.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 4.3% | 5.7% | 4.2% | -18.9% | -23.9% | -25.8% | -13.6% | -8.8% | 15.1% | 15.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Ikena Oncology against the 5 most active filers in the same SIC group.